Immuron CEO Presentation at AusBiotech Invest 2025 Conference

Immuron Limited announced that its CEO, Steven Lydeamore, will present at the AusBiotech Invest 2025 conference on October 21, 2025, in Melbourne, Australia. The presentation will cover Immuron's proprietary technology platform, which focuses on developing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. Key products include Travelan®, an orally administered passive immunotherapy for travelers' diarrhea, and IMM-529, an adjunctive therapy for recurrent Clostridioides difficile infection (CDI). The company reported strong financial performance for FY2025, with global sales revenue increasing by 49% to $7.3 million. Immuron's pipeline includes ongoing Phase 3 trials for IMM-124E (Travelan®) and Phase 2 trials for IMM-529, with potential peak U.S. sales projected at $102 million and $400 million, respectively.